Mayo Clinic Proceedings Home

Role of the Clinical Laboratory in the Diagnosis and Management of Malignant Melanoma

      The biosynthesis of melanin from tyrosine is reviewed as the basis for assessment of laboratory tests that might potentially aid in the diagnosis and management of patients with malignant melanoma. These tests include qualitative and quantitative assays for the intermediates in metabolism of melanin and catecholamines, enzyme assays, metal ion analyses, and, most recently, immunoassays. Although currently no role exists for the clinical laboratory in the early diagnosis of malignant melanoma, serial quantitative analyses of total or individual melanogens or of catecholamine metabolites in urine or plasma specimens may be of value in the management of patients with this disorder. Immunologically based methods for the diagnosis and management of malignant melanoma hold some promise for the future.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Quevedo Jr, WC
        • Fleischmann RD
        Developmental biology of mammalian melanocytes.
        J Invest Dermatol. 1980; 75: 116-120
        • Pawelek JM
        • Körner AM
        The biosynthesis of mammalian melanin.
        Am Sci. 1982; 70: 136-145
        • Prota G
        Recent advances in the chemistry of melanogenesis in mammals.
        J Invest Dermatol. 1980; 75: 122-127
        • Riley PA
        Melanins and melanogenesis.
        Pathobiol Annu. 1980; 10: 223-251
        • Schwartz MK
        Biochemistry of malignant melanoma.
        Ann Clin Lab Sci. 1976; 6: 56-64
        • Pavel S
        • Muskiet FAJ
        Eumelanin (precursor) metabolites as markers for pigmented malignant melanoma: a preliminary report.
        Cancer Detect Prev. 1983; 6: 311-316
        • Barber JI
        • Townsend D
        • Olds DP
        • King RA
        Dopachrome oxidoreductase: a new enzyme in the pigment pathway.
        J Invest Dermatol. 1984; 83: 145-149
        • Wolff K
        Melanocyte-keratinocyte interactions in vivo: the fate of melanosomes.
        Yale J Biol Med. 1973; 46: 384-396
        • Bennett C
        • Cooke KB
        Further characterization of a melanoma-specific protein from human urine.
        Br J Cancer. 1980; 41: 734-744
        • Sulitzeanu D
        Human cancer-associated antigens: present status and implications for immunodiagnosis.
        Adv Cancer Res. 1985; 44: 1-42
        • Johnson JP
        • Riethmüller G
        Monoclonal antibodies and melanomas.
        in: Ferrone S Dierich MP Handbook of Monoclonal Antibodies: Applications in Biology and Medicine. Noyes Publications, Park Ridge, New Jersey1985: 347-359
        • Gupta RK
        • Huth JF
        • Korn EL
        • Morton DL
        Prognostic significance of urinary antigen analysis by enzyme-linked immunosorbent assay in melanoma patients.
        Diag Immunol. 1983; 1: 303-309
        • Schultz AL
        Urine analysis.
        in: Kaplan LA Pesce AJ Clinical Chemistry: Theory, Analysis, and Correlation. CV Mosby Company, St. Louis1984: 1391-1393
        • Silverman LM
        • Christenson RH
        • Grant GH
        Amino acids and proteins.
        in: Tietz NW Textbook of Clinical Chemistry. WB Saunders Company, Philadelphia1986: 554-555
        • Bradley M
        • Schumann GB
        Examination of urine.
        in: Henry JB Clinical Diagnosis and Management by Laboratory Methods. Seventeenth edition. WB Saunders Company, Philadelphia1984: 422-443
        • Von Jaksch R
        Beitrag zur Kenntniss des Verhaltens des Harnes bei der Melanurie.
        Hoppe Seylers Z Physiol Chem. 1889; 13: 385-394
        • Thormählen J
        Mittheilung über einen noch nicht bekannten Körper in pathologischem Menschenham.
        Arch Pathol Anat. 1887; 108: 317-322
        • Pechan Z
        Studien über melanine und Melanogenese. III. Auswertung der Thormählen'schen Reaktion für die Bestimmung des Indol-Melanogens.
        Neoplasma. 1959; 6: 397-403
        • Beeler MF
        • Henry JB
        Melanogenuria—evaluation of several commonly used laboratory procedures.
        JAMA. 1961; 176: 52-54
        • Weiss M
        Die Urochromogenprobe und andere Harnreaktionen.
        Klin Wochenschr. 1922; 1: 694-697
        • Scott RE
        • Ward VL
        • Grinstead GF
        • Stevens BS
        • Wilson DM
        Melanogenuria: laboratory evaluation of the qualitative Thormählen and ferric chloride tests and their clinical utility.
        Clin Chem. 1988; 34: 582-585
        • Horčičko J
        • Borovanský J
        • Kubíková M
        • Duchoň J
        • Duchková H
        Urinary excretion of zinc and magnesium in malignant melanoma.
        Clin Chim Acta. 1980; 104: 377-380
        • Fisher GL
        • Spitler LE
        • McNeill KL
        • Rosenblatt LS
        Serum copper and zinc levels in melanoma patients.
        Cancer. 1981; 47: 1838-1844
        • Horčičko J
        • Pavel S
        • Borovanský J
        • Duchoň J
        Excretion of melanogens and zinc during the growth of melanoma in hamsters.
        Neoplasma. 1979; 26: 471-475
        • Horčičko J
        • Pantůček M
        Hypozincemia in patients with malignant melanoma.
        Clin Chim Acta. 1983; 130: 279-282
        • Matouš B
        • Cigánek EF
        • Budešínská A
        • Duchoň J
        Biochemical markers of malignant melanoma.
        Neoplasma. 1987; 34: 77-84
        • Mojamdar M
        • Ichihashi M
        • Mishima Y
        Tyrosinase and γ-glutamyl transpeptidase in 5-S-cysteinyldopa genesis within melanotic and amelanotic melanomas.
        J Dermatol (Tokyo). 1982; 9: 73-77
        • Chen YM
        • Chavin W
        Tyrosinase activity in a highly pigmented human melanoma and in Negro skin.
        Proc Soc Exp Biol Med. 1974; 145: 695-698
        • Duchoň J
        • Matouš B
        • Pavel S
        Melanogenuria as consequence of elevated tyrosinase activity in melanoma.
        Acta Univ Carol [Med Monogr] (Praha). 1977; 78: 139-144
        • Chen YM
        • Lim BT
        • Chavin W
        Serum tyrosinase in malignant disease, its activity, and the electrophoretic patterns of the enzyme as carried by immunoglobulins.
        Cancer Res. 1979; 39: 3485-3490
        • Pavel S
        • Matouš B
        • Duchoň J
        Simple screening test for estimation of some phenolic and indolic compounds in urine: application to melanoma.
        J Invest Dermatol. 1978; 70: 197-199
        • Gan EV
        • Haberman HF
        • Menon IA
        A simple and sensitive test for the determination of phenolic compounds in urine and its application to melanoma.
        J Invest Dermatol. 1975; 64: 139-144
        • Haberman HF
        • Gan EV
        • Menon IA
        Comparison of various methods for determination of melanogens as a diagnostic test for melanoma.
        Pigment Cell. 1976; 2: 297-309
        • Pavel S
        • van der Slik W
        Analysis of eumelanin-related indolic compounds in urine by high-performance liquid chromatography with fluorimetric detection.
        J Chromatogr. 1986; 375: 392-398
        • Pavel S
        • Elzinga H
        • Muskiet FAJ
        • Smit JM
        • Mulder NH
        • Koops HS
        Eumelanin-related indolic compounds in the urine of treated melanoma patients.
        J Clin Chem Clin Biochem. 1986; 24: 167-173
        • Eppinger H
        Uber Melanurie.
        Biochem Ztschr. 1910; 28: 181-192
        • Duchoň J
        • Pechan Z
        The biochemical and clinical significance of melanogenuria.
        Ann NY Acad Sci. 1963; 100: 1048-1068
        • Matouš B
        • Mechl Z
        • Šopková B
        • Duchoň J
        • Pavel S
        • Buděšínská A
        • Kočent A
        The excretion of Thormählen positive melanogens in melanoma patients and its clinical significance.
        Eur J Cancer. 1980; 16: 383-388
        • Matouš B
        • Pavel S
        • Buděšínská A
        • Duchoň J
        • Mechl Z
        • Šopková B
        Comparison of the excretion of different types of melanogens in the melanoma patients.
        Neoplasma. 1979; 26: 597-602
        • Morishima T
        • Tatsumi F
        • Fukada E
        • Saito M
        • Fujita M
        • Nagashima N
        • Hanawa S
        Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
        Arch Dermatol Res. 1983; 275: 76-79
        • Hansson C
        • Agrup G
        • Rorsman H
        • Rosengren A-M
        • Rosengren E
        • Edholm L-E
        Analysis of cysteinyldopas, dopa, dopamine, noradrenaline and adrenaline in serum and urine using high-performance liquid chromatography and electrochemical detection.
        J Chromatogr. 1979; 162: 7-22
        • Nixon PF
        The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
        Aust N Z J Surg. 1978; 48: 17-21
        • Argue G
        • Agrup P
        • Andersson T
        • Hafström L
        • Hansson C
        • Jacobsson S
        • Jönsson P-E
        • Rorsman H
        • Rosengren A-M
        • Rosengren E
        Five years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
        Acta Derm Venereol (Stockh). 1979; 59: 381-388
        • Rorsman H
        • Rosengren A-M
        • Rosengren E
        A sensitive method for determination of 5-S-cysteinyldopa.
        Acta Derm Venereol (Stockh). 1973; 53: 248-250
        • Graef V
        • Paul E
        Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
        Br J Dermatol. 1982; 106: 53-57
        • Mojamdar M
        • Ichihashi M
        • Mishima Y
        Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and its urinary excretion.
        J Dermatol (Tokyo). 1979; 6: 379-382
        • Voorhess ML
        Urinary excretion of DOPA and metabolites by patients with melanoma.
        Cancer. 1970; 26: 146-149
        • Hinterberger H
        • Freedman A
        • Bartholomew RJ
        Precursors of melanin in the urine and 3,4-dihydroxyphenylala-nine in the blood of patients with malignant melanoma.
        Pigment Cell. 1973; 1: 312-316
        • Faraj BA
        • Camp VM
        • Murray DR
        • Kutner M
        • Hearn J
        • Nixon D
        Plasma L-dopa in the diagnosis of malignant melanoma.
        Clin Chem. 1986; 32: 159-161
        • Tomecki KJ
        • Montague PM
        • Hearing Jr, VJ
        Serum and urine protein differences in patients with malignant melanoma.
        JNCI. 1980; 64: 29-32
        • Ruell P
        • Murray E
        • McCarthy WH
        • Hersey P
        Evaluation of assays to detect immune complexes as an immunodiagnostic aid in patients with melanoma.
        Oncodevel Biol Med. 1982; 3: 1-12
        • Kristensen E
        • Brandslund I
        • Nielson H
        • Svehag S-E
        Prognostic value of assays for circulating immune complexes and natural cytotoxicity in malignant skin melanoma (stages I and II).
        Cancer Immunol Immunother. 1980; 9: 31-36
        • Henriques III, HF
        • Phillips TM
        Immune-complex assays: a clinical and laboratory review.
        Am Clin Prod Rev. 1987; 6: 28-31
        • Herberman RB
        • Bordes M
        • Lambert PH
        • Luthra HS
        • Robins RA
        • Sizaret P
        • Theofilopoulos A
        Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer.
        Int J Cancer. 1981; 27: 569-576
        • Wong JH
        • Gupta RK
        • Morton DL
        Serial determinations of melanoma tumor-associated antigen and antibody in patients with stage I melanoma.
        Arch Surg. 1986; 121: 1342-1345